Release Date: December 7, 2018

Expiration Date: December 7, 2019

Faculty

Amy S. Paller, MS, MD Chair, Department of Dermatology Director, Northwestern University Skin Disease Research Center Walter J. Hamlin Professor of Dermatology Professor of Dermatology and Pediatrics Feinberg School of Medicine Northwestern University Chicago, Illinois Jonathan M. Spergel, MD, PhD Professor of Pediatrics Chief, Allergy Section Stuart E. Starr Endowed Chair of Pediatrics Director, Center for Pediatric Eosinophilic Disease Director, FARE Center of Excellence The Children’s Hospital of Philadelphia Perelman School of Medicine University of Pennsylvania Philadelphia, Pennsylvania

Program Overview

Patients with atopic dermatitis (AD) are sub-optimally managed in current clinical practice and hence report a poor quality of life and high burden from their disease and comorbidities. There remains an unmet need for effective therapies that not only relieve distressing symptoms of AD, but also improve long-term outcomes for patients. An improved understanding of the pathogenesis of AD has led to the development of biologic agents, including dupilumab, which are known to target the underlying pathophysiology of AD. Despite this progress, AD continues to impose a huge healthcare burden due to knowledge and competence deficits among healthcare professionals. There is a need to improve the diagnosis, assessment of severity, treatment, and management of AD to enable improved outcomes and quality of life among patients. This program will include topics that will improve healthcare professionals’ ability to accurately diagnose and recognize AD among patients presenting with eczema by informing participants about updated diagnostic criteria and assessment scores to differentially diagnose AD and its severity. Discussions on updated guidelines, recommendations, and recent clinical evidence to inform treatment decisions to alleviate the symptom burden of AD will be included and evaluated. Clinicians will also learn strategies to improve communication and adherence to treatment, and address to comorbidities of AD.

Target Audience

This educational initiative has been designed for dermatologists, allergists, primary care physicians, nurse practitioners, and physician assistants involved in the management of AD.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

Utilize updated criteria and guidelines to accurately diagnose AD and assess severity
Describe the limitations of currently available therapies in addressing underlying AD pathophysiology
Evaluate recent clinical evidence on the utility of approved and emerging biologic agents to address the underlying pathophysiology of AD
Discuss strategies that will improve patient satisfaction with treatment and reduce the burden of comorbidities

Directions to Learner

There are no fees for participating and receiving CME credit for this activity. During the period of December 7, 2018 through December 7, 2019, participants must:

Read the learning objectives and faculty disclosures
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Media

Internet

Accreditation Statement

Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Integrity Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Contact Information

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Disclosure of Conflicts of Interest

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities: Amy S. Paller, MS, MD Consulting Fees: AbbVie, Asana, Dermavant, Dermira, Galderma, Eli Lilly, Forte, Leo, Matrisys, Menlo, Morphosys/Galapagos, Novartis Pharmaceuticals Corporation, Pfizer, Promius, Sanofi Genzyme and Regeneron Pharmaceuticals Contracted Research: AbbVie, Anaptysbio, Eli Lilly, Galderma, Incyte, Leo, Janssen, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals Jonathan M. Spergel, MD, PhD Royalty: Up-To-Date Consulting Fees: Regeneron Pharmaceuticals, Shire Contracted Research: AbbVie, Regeneron Pharmaceuticals Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Privacy Policy

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

Minimum System Requirements

Windows 98, 2000, XP, 2003, Vista, and 7 Internet Explorer 6/7 Firefox 2 Mozilla 1.7 or higher Netscape 8.1 or higher Flash Player 10 Mac OS X 10.3, 10.4 Safari 1.3 (Mac OS 10.3) Safari 2.0 or higher (Mac OS 10.4) Firefox 2 Flash Player 10 Use of Internet Explorer browser is not recommended. Click here for more information on minimum system requirements.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Provider Statement

Provided by Integrity Continuing Education, Inc.

Supporter Acknowledgement

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Strategies to Provide Individualized Treatment in Moderate-to-Severe Atopic Dermatitis